chartexchange

MESO
Mesoblast Limited
stockNASDAQADR

Market OpenNov 19, 2026 3:00:07 PM EST
11.14USD-4.338%(-0.50)192,974
9.4800Bid12.72Ask3.2400Spread
Loading…
Loading…
Healthcare
Biotechnology
CEO
Silviu Itescu
HQ
Melbourne, VIC, Australia
Previous Close
$11.64
Beta
1.31
52-Week High
$21.50 2026-01-09
52-Week Low
$11.60 2026-11-18
SMA 50
$14.04
SMA 200
$15.13
Avg. Vol 10D
187,915
Avg. Vol 30D
269,120
Avg. Vol 90D
242,641
Relative Vol
0.71
129.85M
83.20M
10.5900%
4,216
Jan 10, 2024 · 1-for-2 (reverse)
Nov 18, 2026
Nov 17, 2026
Nov 15, 2026
Nov 10, 2026
MESO Profile

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (mlcs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. our 'off-the-shelf' products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. our licensee in japan has launched its mlc-based product for acute graft versus host disease in children and adults in japan. it is the first allogeneic cell-based product in japan to be fully approved in japan. we believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the united states. our lead product candidates under investigation are: • mpc-150-im for chronic heart failure • mpc-06-id for chronic low back pain due to disc degeneration • msc-100-iv for acute graf

MESO Performance
PeriodPriceDateChangeBeta
1W13.102026-11-12-15.04%3.643
1M11.952026-10-19-6.86%0.809
3M17.132026-08-19-35.03%1.065
6M14.552026-05-19-23.50%1.076
1Y14.852025-11-19-25.05%1.310
2Y10.822024-11-19+2.87%—
5Y12.482021-11-19-10.82%0.342
MESO Stock Summary

Mesoblast Limited (NASDAQ:MESO) stock price today is $11.13, and today's volume is 190,627. MESO is down 4.381% today. The 30 day average volume is 269,120. MESO market cap is $1.45B with 129.85M shares outstanding.